Overview and Scope
Myelodysplastic syndrome (MDS) is a group of disorders characterized by the malfunctioning or abnormal development of bone marrow cells, leading to ineffective blood cell production. Myelodysplastic syndrome treatment improves blood cell counts, alleviates symptoms and delays disease progression. Myelodysplastic syndrome (MDS) can progress to acute myeloid leukemia (AML), a more aggressive form of blood cancer.
Sizing and Forecast
The myelodysplastic syndrome market size has grown rapidly in recent years. It will grow from $2.3 billion in 2023 to $2.56 billion in 2024 at a compound annual growth rate (CAGR) of 11.5%. The growth in the historic period can be attributed to increasing prevalence of myelodysplastic syndrome, growing awareness about myelodysplastic syndrome treatment, rising healthcare spending, government initiatives.
The myelodysplastic syndrome market size is expected to see rapid growth in the next few years. It will grow to $3.78 billion in 2028 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to aging population, adoption of combination therapies, investment in hematologic research, personalized medicine. Major trends in the forecast period include innovative treatments for myelodysplastic syndrome, advancements in diagnostic tools and techniques, clinical trials, collaborative research.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/myelodysplastic-syndrome-global-market-report
Segmentation & Regional Insights
The myelodysplastic syndrome market covered in this report is segmented –
1) By Type: Myelodysplastic Syndrome With Unilineage Dysplasia; Myelodysplastic Syndrome With Multilineage Dysplasia; Myelodysplastic Syndrome With Ring Sideroblasts; Other Types
2) By Drug: Azacitidine; Lenalidomide; Decitabine; Deferasirox
3) By Treatment: Supportive Therapy; Growth Factors; Chemotherapy; Stem Cell Transplant; Other Treatments
4) By Route Of Administration: Oral; Injectable; Other Routes Of Administrations
5) By End-Users: Hospitals; Homecare; Specialty Centers; Other End-Users
North America was the largest region in the myelodysplastic syndrome market in 2023. The regions covered in myelodysplastic syndrome (MDS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12920&type=smp
Major Driver Impacting Market Growth
The increasing incidence of rare blood cancers is expected to propel the growth of the myelodysplastic syndrome (MDS) market going forward. Blood cancers are types of hematologic malignancies with a low incidence rate in the population and originate from the cells of the bone marrow, lymph nodes and other components of the blood and immune system. Myelodysplastic syndrome (MDS) treatment aims to manage the condition by improving blood cell production and addressing associated symptoms to prevent the progression of blood cancer in the bone marrow. For instance, in June 2021, according to the Leukemia Foundation, an Australia-based national charitable organization, more than 110,000 people are coping with blood disorders. Additionally, by 2035, more than 275,000 Australians are predicted to have blood disorders. Therefore, the increasing incidence of blood cancer drives the growth of the myelodysplastic syndrome (MDS) market.
Key Industry Players
Major players in the myelodysplastic syndrome market are Pfizer Inc., Johnson and Johnson Limited, AbbVie Inc., Bayer AG, Novartis AG, Merck & Co., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca Plc., Takeda Pharmaceutical Company Limited, Medtronic PLC, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Otsuka Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Ltd., Jazz Pharmaceuticals, Dr. Reddy’s Laboratories Ltd., Lupin Limited, BeiGene, Janssen Biotech, Accord Healthcare, Acceleron Pharma Inc.
The myelodysplastic syndrome market report table of contents includes:
1. Executive Summary
2.Myelodysplastic Syndrome Market Characteristics
3.Myelodysplastic Syndrome Market Trends And Strategies
4.Myelodysplastic Syndrome Market analysis
5.Myelodysplastic Syndrome Market Size And Growth
6.Myelodysplastic Syndrome Segmentation
7.Myelodysplastic Syndrome Regional And Country Analysis
.
.
.
27.Myelodysplastic Syndrome Competitive Landscape And Company Profiles
28. Myelodysplastic SyndromeKey Mergers And Acquisitions
29.Myelodysplastic Syndrome Future Outlook and Potential Analysis
TOP MAJOR PLAYERS:
- Pfizer Inc.
- Johnson and Johnson Limited
- AbbVie Inc.
- Bayer AG
- Novartis AG
- Merck & Co.
Explore the trending research reports from TBRC:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Global Myelodysplastic Syndrome (MDS) Drugs Market Research Report: Information by Type (Chemotherapy, Immunomodulatory Drugs and others), Type of Syndrome (Metals & Alloys, Bioabsorbable, Ceramics, Polymers and others), Application (Refractory Cytopenia with Multilineage Dysplasia, Refractory Anemia, Refractory Anemia with Excess Blasts, Refractory Anemia with Ringed Sideroblasts, Refractory Cytopenia with Multilineage Dysplasia and others), Route of Administration (Oral, Parenteral and others), End User (Hospitals, Clinics, Ambulatory Surgical Centers and others) and Region - Global Forecast till 2025Myelodysplastic syndrome (MDS) are a group of cancers in which blood cells in the bone marrow do not mature making it susceptible to other diseases.
When left untreated, MDS can expand to a type of cancer affecting the bone marrow cells known as acute myeloid leukemia (AML).
The global myelodysplastic syndrome drugs market report by Market Research Future (MRFR) consists of the various developments in drug discovery, moves by existing players, and other pertinent factors.Myelodysplastic Syndrome (MDS) Drugs Market OverviewThe Global MDS Drugs Market is estimated to reach a significant value by showcasing a CAGR of 10.1% during the forecast period (2018-2025).
It stood at USD 1,581.59 million in 2018.
Approval of decitabine, a product of Lupin Ltd, by the U.S. FDA is an indicator of the acceptance of new drugs by the market.The rising numbers of the geriatric populace, regulatory approvals, and advocation of clinical trials pertaining to MDS are other major drivers of the global myelodysplastic syndrome drugs market.
Improvement of healthcare services by cancer centers and development of novel therapeutics can fuel the market growth successfully till 2025.But adverse effects of the drugs and risk of infections during blood transfusions can impede the market growth.Myelodysplastic Syndrome (MDS) Drugs Market Competition OutlookSandoz, Otsuka America Pharmaceutical Inc., Celgene Europe Limited, Lupin Ltd Corporation, Shilpa Medicare Limited, Celgene Corporation, Johnson & Johnson, Reddy's Laboratories, Inc., Sun Pharmaceutical Industries Inc., and BluePoint Laboratories are prominent names in the global myelodysplastic syndrome drugs market.Myelodysplastic Syndrome (MDS) Drugs Industry NewsOnconova Therapeutics Inc has decided to collaborate with Mission Bio for using the latter’s platform for providing breakthrough treatments for MDS.
